Plitidepsin has demonstrated its efficacy in studies conducted in against SARS-CoV-2 and other types of coronaviruses. Plitidepsin has been exhaustively investigated in “in vitro” and “in vivo” studies in patients at several leading research centers worldwide, including the National Biotechnology Center of the Spanish National Research Council (CNB-CSIC), lead by Dr. Luis Enjuanes; the Institute of Emerging Pathogens at Mount Sinai Hospital in New York, with Dr. Adolfo García Sastre; Germans Trias i Pujol Hospital in Barcelona, directed by Dr. Bonaventura Clotet; and the Institut Pasteur in Korea .

These sets of translational research confirm, consistently, that nanolomar concentations of plitidepsin are able to eliminate COVID19 colonies.

Notably, such active nanomolar concentrations have been projected to be attainable in patients treated with subtoxic doses of plitidepsin.